ALGN vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ALGN's Piotroski F-Score of 4/9 indicates weak financial health, signaling potential operational inefficiencies despite stable profitability. The absence of an Altman Z-Score raises concern about default risk, though the company's extremely low debt/equity ratio (0.03) and strong liquidity support financial stability. The stock trades near its intrinsic value of $166.68 but at a premium to the Graham Number ($84.93), reflecting high growth expectations. Analysts maintain a 'buy' consensus with a target price of $201.57, suggesting upside, though recent insider selling and inconsistent earnings surprises temper enthusiasm.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
ALGN vs LLY: Head-to-Head Comparison
This page compares Align Technology, Inc. (ALGN) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.